SECTOR
UPDATE

2026. 3. 27

Innovation Team

Keunhee seo, Ph.D. Head of Team
keunhee.seo@samsung.com

Suhan Shin Research Associate
shn.shin@samsung.com

※ All material presented in this report, unless specifically indicated otherwise, is under copyright to Samsung Securities. None of the material, nor its content, nor any copy of it, may be altered in any form or by any means, transmitted, copied, or distributed to any other party, without the prior express written permission of Samsung Securities. This memorandum is based upon information available to the public. While we have taken all reasonable care to ensure its reliability, we do not guarantee that it is accurate or complete. This memorandum is not intended to be an offer, or a solicitation of any offer, to buy or sell the securities mentioned herein. Samsung Securities shall not be liable whatsoever for any loss, direct or consequential, arising from any use of this memorandum or its contents. Statements, if any, relating to affiliates of Samsung Securities are also based upon information available to the public and do not necessarily represent the views of the management of such affiliates. This report has been prepared without any undue external influence or interference, and accurately reflects the personal views of the analyst(s) on the company(ies) herein.

Samsung Securities



The Korean version of this report was published on Mar 5

Healthcare Industry

RNAissance 2026: From optimism to conviction

RNAissance 2026

RNA 2.0: The great transition to treating chronic disease

Until now, when you thought of RNA treatments, you might have only considered them for COVID-19 vaccines or drugs for extremely rare diseases. However, RNA is no longer just a trend—it has established itself as standard technology that directly modifies our body's blueprint to cure diseases. As of 2026, RNA has become the most powerful tool for addressing common widespread chronic diseases like obesity and hypertension. With the advent of an era where diseases can be managed with just two injections per year, global pharmas are busy securing companies that possess RNA technologies in order to capture a slice of this potentially colossal market.

In the past, RNA drugs primarily targeted the liver, limiting their therapeutic scope. However, technologies for the precise delivery of drugs to organs such as the lungs, muscles, and even brain tissue have now reached an advanced stage. Additionally, next-generation RNA technologies that last longer in the body or replicate themselves have significantly improved treatment efficacy. Particularly, with AI now involved in drug design, the speed at which new drugs are being developed has become incomparably faster.

Companies like Alnylam Pharmaceuticals and Ionis Pharmaceuticals, which are leading the market, have already proven their strength by successfully launching chronic disease treatments. In Korea, ST Pharm, which supplies RNA raw materials to global pharmas, is emerging as a major beneficiary of recent regulatory changes in the US, showcasing its unique presence. Furthermore, domestic companies like Olix pharmaceuticals and Rznomics, which are collaborating on the global stage in areas such as obesity treatments and brain diseases with their own distinctive technologies, are also showing themselves to be key players that ought not to be overlooked.

Direct beneficiary of oligo market growth

ST Pharm (237690; BUY; target price: KRW190,000)

- **2026 outlook:** We forecast ST Pharm's 2026 sales will grow 25.1% to KRW414.6b (including oligonucleotide CMO sales of KRW281b (up 18.2%)) and its operating profit will rise 28.8% to KRW70.9b. With the completion of the expansion at the Ansan Banwol facility, its production capacity has doubled. As a result, significantly greater sales will likely be recognized. A robust order backlog, which is composed of long-term supply agreements with major global pharmas, have given the firm clear sales visibility. As utilization rates rise, the company's cost structure should gradually improve.
- **Oligonucleotide market outlook:** The RNA-based therapeutics market has entered a phase of structural growth. Originally focused on treating rare diseases, RNA-based therapies are now being developed for more common conditions like heart disease, cancer, central nervous system disorders, and infections. The number of approvals by the FDA and EMA has been rising every year. Thanks to advances in GalNAc conjugate technology, these drugs can now be given as subcutaneous injections, making treatment much easier for patients. Because of how they work, they are also showing higher success rates in clinical trials. The global oligonucleotide CDMO market is projected to grow at a CAGR of at least 20% until 2030 (according to Towards Healthcare) at a time when there are few companies that have GMP-certified production facilities (to make these drugs at scale). This gives ST Pharm, which has strong manufacturing capabilities, a structural edge.
- **Maintaining BUY and target price of KRW190,000:** The already confirmed order volumes provide downside support for its earnings, but additional earnings upside potential may be limited in the short term. That said, what makes this company worth watching is its partnership with Ionis Pharmaceuticals. As an API supplier to Ionis's pipeline, ST Pharm stands to benefit from long-term volume growth as Ionis advances its drug candidates. ST Pharm's valuation premium should hinge on its medium- to long-term growth story—tied to the clinical success and speed of commercialization of Ionis's pipeline—rather than on its short-term earnings performance.

AT A GLANCE

Current price	KRW148,800
Market cap	KRW3,092b
Shares (float)	20,777,000 shares
120-day avg. trading volume	KRW27b
52-week low/high	KRW67,300 / KRW160,600
Relative return (3m/6m)	4.5% / 10.4%
Dividend yield (2025P)	0.4%
BVPS (2025P)	KRW28,377
Floating share ratio	62.0%
Foreign ownership	10.7%
Major shareholder	Dong-A Socio Holdings et al. (37.5%)

Key data

	2024	2025P	2026E	2027E
Revenue (KRWb)	274	332	415	513
Operating profit (KRWb)	28	55	71	117
Net income (controlling) (KRWb)	35	55	74	114
EPS (adj) (KRW)	1,780	2,700	3,565	5,486
EPS (adj) growth (%)	71.0	51.7	32.1	53.9
EBITDA margin (%)	19.5	25.7	25.1	28.9
ROE (%)	7.8	10.1	12.0	16.2
P/E (adj) (x)	50.0	44.2	41.8	27.1
P/B (x)	3.6	4.2	4.7	4.1
EV/EBITDA (x)	34.8	29.6	29.7	20.1
Dividend yield (%)	0.6	0.3	0.3	0.3

Note: Based on Mar 5 close
Source: ST Pharm, Samsung Securities estimate

ST Pharm: A global top-tier oligonucleotide CMO

▶ Clients' expanding commercialization projects coupled with ST Pharm's strengthening manufacturing capabilities

- Thanks to rising commercial volumes of oligonucleotide APIs, ST Pharm's sales in 2026 should grow 25.1% to KRW414.6b (including oligonucleotide CMO sales of KRW281b (up 18.2%)) and its operating profit looks set to increase 28.8% to KRW70.9b.
- A new production line should come fully online in 2026, allowing ST Pharm to meet global demand and secure the largest production capacity of any single facility in the world.
- Profitability is likely to improve, as: 1) the large-scale capacity expansion should reduce its production costs per unit; and 2) more pipeline candidates transition to commercialization phases, leading to higher utilization rates. With its advanced process technologies, the company is solidifying its position as a top-tier player in the oligonucleotide CDMO market and is on track to reach KRW500b in sales *pa* by 2027.

ST Pharm: Earnings trend



Source: ST Pharm, Samsung Securities estimate

ST Pharm: Operating profit, by division



Source: Samsung Securities

CMO volumes bound for big global pharmas to rise

Prescriptions for key clients' products projected to climb

- Rytelo (Imetelstat): Currently marketed for the treatment of transfusion-dependent anemia in patients with low- or intermediate-1-risk myelodysplastic syndromes (MDS).
- Leqvio (Inclisiran): Poised for substantial growth in insurance coverage and prescription volume after large-scale cardiovascular outcome trials (CVOTs) deliver results after 2026.
- Tryngolza (Olezarsen): Launched in 2025 for familial chylomicronemia syndrome (FCS). The product is rapidly penetrating the market, achieving USD110m in sales in 2025. Adding the severe hypertriglyceridemia (sHTG) indication in 2026, the target patient population would surge to tens of thousands, driving substantial sales growth.

ST Pharm: Major customers and products

Company	Notes
Geron	• Rytelo (Imetelstat): Telomerase inhibition. • Approved for adults with transfusion-dependent anemia among low-risk and intermediate-1 risk MDS patients who are resistant to or cannot use ESAs. • Preparing for European market entry (1H26). • P3 underway for MF; P2 underway for AML.
Novartis	• Leqvio (Inclisiran): PCSK9 Inhibitor. • Adjunctive therapy for atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia; high-risk dyslipidemia after statin+ezetimibe.

Source: Samsung Securities

ST Pharm: Major customers and products

Company	Notes
Biogen	• Spinraza (Nusinersen): SMN2 gene splicing regulation. • Approved for infant-to-adult SMA treatment with 4-month maintenance dosing. • Competitors include Zolgensma (one-time, gene therapy), Evrysdi (oral), Apitegromab (under review). • Biogen's next-gen drug Salanersen: once yearly, P3 underway.
Ionis	• Tryngolza (Olezarsen): ApoC-III inhibition. • Launched for FCS, dosed monthly. • P3 results for sHTG, HTG (non-hereditary severe and moderate hypertriglyceridemia) announced (Sep 2, 2025) and PDUFA (Jun 2026). • Requires 1 g of oligo/person *pa* (FCS approx. 5,000 people globally; HTG 0.2m-0.3m people needing 200-300 kg *pa*). • Competitor is Arrowhead's Plozasiran (FCS, P3).

Source: Samsung Securities

Oligonucleotide demand forecasts

Ionis' pipeline development status and annual production volume

Therapeutic	Disease	Target	Stage	Single dose (mg)	Dosing interval (1yr)	Annual dose/ person (mg)	Target patients 10k)*	Annual req. production (kg)	Note
Spinraza(Nusinersen)	**SMA**	**SMN2**	**M*****	**12**	**7**	**84**	**10,000**	**1**	**Biogen**
Waylivra(Volanersorsen)	FCS *	ApoCIII	M	284	52	14,768	2,000	29	Europe SOBI
WAINUA(Eplontersen)	hATTR-PN**	TTR	M	285	48	13,680	5,000	74	AstraZeneca
Tryngolza(Olezarsen)	**FCS**	**ApoCIII**	**M**	**45**	**26**	**2,340**	**4,000**	**9**	**Self-commercialized**
Tegsedi(Inotersen)	hATTR-PN **	TTR	M	80	52	2,080	10,000	20	Self-commercialized
Pelacarsen	**Cardiovascular diseases**	**Apo(a)**	**P3**	**80**	**12**	**960**	**1,000,000**	**960**	**Novartis**
Sefaxersen	**IgA nephropathy**	**Factor B**	**P3**	**80**	**26**	**82,080**	**8,000**	**16.6**	**Roche**
Bepirovirsen	**Hepatitis B treatment**	**HBV**	**P3**	**300**	**6**	**1,800**	**1,000,000**	**1,800**	**GSK**
Tonlamarsen	Hypertension	Angiotensinogen	P2	120	4	480	10,000	4.8	Kardigan
Vupanorsen	Hyperlipidemia treatment	ANGPTL3	P2	80	12	960	1,380,000	1,325	Pfizer
ION449(AZD8233)	Dyslipidemia	PCSK9	P2	120	2	360	1,380,000	497	AstraZeneca
IONIS-MAPTrx	Alzheimer's, dementia	TAU	P2	100	4	400	1,500,000	600	Biogen
Tominersen	Huntington's disease	HTT	P2	200	12	2,400	1,000	2.4	Roche
ION306	Spinal muscular atrophy (SMA)	SMN2	P2	20	7	140	10,000	1.4	Biogen
Olezarsen	**Cardiovascular diseases**	**ApoCIII**	**P3**	**50**	**12**	**600**	**1,000,000**	**600**	
Donidarsen	**Hereditary angioedema**	**PKK**	**P3**	**80**	**12**	**960**	**20,000**	**20**	
Zilganersen	Alexander disease	GFAP	P3	100	6	600	3,000	1.8	
IONS582	Engelmann disease	UBE3A-ATS	P2	100	12	1,200	1,000	12	
ION269	Alzheimer's disease	APP	P2	200	12	2,400	1,500,000	2,400	
ION717	Prion diseases (e.g., mad cow disease)	PRNP	P2	100	12	1,200	2,000	2.4	
ION356	Pelizaeus-Merzbacher disease	PLP1	P2	80	6+	480	1,000	0.48	
ION859	Parkinson's disease	LRRK2	P2	200	12	2,400	500,000	1,200	
ION464	Multiple system atrophy/Parkinson's disease	SNCA	P2	150	12	1,800	1,000,000	180	
ION440	MECP2 duplication syndrome	MECP2	P2	60	6	360	300,000	1.1	

Note: P2 materials subject to dose change; assume 10-20% of target patients in advanced countries(US, Europe, Japan, China, etc); *Only a very small number of patients genetically linked to LPL. **Tegsedi hATTR-PN, Wainua hATTR-PN, ATTR-CM ***Marketed Source: Each company, Samsung Securities estimate

ST Pharm's order backlog, by product line

Product (Unit: '000)	Order date	Delivery	Indication	Currency	Total order	Delivered	Backlog
Oligonucleotide-based new drug active pharmaceutical ingredient (API) (oligonucleotide)	May 2023	Dec 2025	Blood cancer (commercialization)	USD	18,691	12,635	6,056
	Jul 2024	Dec 2025	Blood cancer (commercialization)	USD	27,758	22,038	5,720
	Jul 2024	Dec 2025	Blood cancer (commercialization)	USD	7,971	2,656	5,315
	Aug 2024	Dec 2026	Hyperlipidemia (commercialization)	USD	63,263	29,719	33,544
	Dec 2024	Dec 2026	Blood cancer (commercialization)	USD	10,486	-	10,486
	Nov 2024	Dec 2025	Hereditary angioedema (Phase 3)	USD	1,687	-	1,687
	Jan 2025	Dec 2027	Blood cancer (commercialization)	USD	14,518	-	14,518
	Jan 2025	Mar 2026	Atherosclerosis (Phase 3)	USD	14,665	5,206	9,459
	Jan 2025	Jun 2026	IgA nephropathy (Phase 3)	CHF	2,269	-	2,269
	Feb 2025	Jun 2026	IgA nephropathy (Phase 3)	CHF	1,361	-	1,361
	Mar 2025	Dec 2025	Familial chylomicronemia	USD	11,040	-	11,040
	Mar 2025	Dec 2026	Blood cancer (commercialization)	USD	14,275	-	14,275
	Mar 2025	Dec 2026	Blood cancer (commercialization)	USD	13,482	-	13,482
	Mar 2025	Dec 2026	Unrevealed siRNA	USD	3,258	-	3,258
	May 2025	Feb 2026	Dry eye disease	CHF	2,073	-	2,073
	Jun 2025	Apr 2026	Familial chylomicronemia	USD	11,040	-	11,040
	Jun 2025	Apr 2026	Familial chylomicronemia	USD	5,520	-	5,520
	Jun 2025	Dec 2026	Blood cancer (commercialization)	USD	13,285	-	13,285
	Jun 2025	Dec 2025	Diabetes	USD	1,690	-	1,690
	Jul 2025	Dec 2026	Blood cancer (commercialization)	USD	7,688	-	7,688
	Aug 2025	Aug 2026	Huntington's disease	CHF	1,240	-	1,240
	Jan 2026	Dec 2026	Severe hypertriglyceridemia	USD	56,340	-	56,340
Free support for facility investment by global pharmas and payment of facility usage fees	Jan 2020	Dec 2030	-	CHF	54,353	35,702	18,651
Monomers	Oct 2024	Dec 2025	MOR-PA	USD	3,980	717	3,263
Small molecule chemically synthesized new drug API	Apr 2024	Jun 2025	Pediatric SMA	USD	4,333	3,905	428
	Jul 2024	Sep 2025		USD	2,889	-	2,889
	Jan 2025	Oct 2025		USD	7,222	-	7,222
	May 2025	Sep 2026		USD	7,222	-	7,222
	May 2025	Sep 2026		USD	7,666	-	7,666
	Jun 2025	Sep 2026		USD	7,666	-	7,666
	Apr 2025	Apr 2026	Undisclosed	USD	5,029	-	5,029
Generic API	Dec 2024	Dec 2025	MRI contrast agent	USD	7,665	-	7,665
	Jul 2025	Oct 2026		USD	7,194	-	7,194
Sum				USD	357,523	76,876	280,647
				CHF	61,296	35,702	25,594

Note: Based on 3Q25 business report, reflecting new orders, excluding fully delivered orders
Source: ST Pharm, Samsung Securities

Beyond the liver, to fat and the brain

Olix Pharmaceuticals (226950; Not rated)

- **Platform validated:** Demonstrating the broad applicability of its platform, Olix Pharmaceuticals has successfully secured strategic partnerships, centered on liver indications, with: 1) Eli Lilly (LLY US; OLX702A, MARC1 obesity/ MASH); 2) L'Oréal (hair and skin regeneration); and 3) Hansoh Pharma (03692 HK; skin and ophthalmology in China).
- **Potential for additional out-licensing:** The key pipeline asset to watch in 2026 is OLX501A (ALK7 inhibitor), which promotes the breakdown of fat through a novel mechanism. This compound shows promise as a standalone therapy and is likely to generate synergies when combined with GLP-1 agonists. Meaningful preclinical data were generated in non-human primates, which data are expected to be disclosed in Mar 2026. A compelling efficacy profile will confirm its strong licensing potential. The firm aims to file an IND application by end-2027, and early partnerships are critical in the fast-moving siRNA obesity segment. The Phase 1b MAD study for OLX702A (MARC1), contracted with Eli Lilly, is expected to be completed in 2Q26. Since the SAD study confirmed drug efficacy of over 10 months, it is anticipated that Lilly will proceed to the next phase of clinical trials after reviewing the MAD results. Additionally, dual-targeting preclinical data is set to be released in 2H26, which is anticipated to serve as a basis for exploring the optimal combination for metabolic diseases in the future. Collaboration with L'Oréal is progressing smoothly, with tangible results expected this year. Milestone payments from clinical progress and potential new deals remain a key upside catalyst.
- **Investment considerations:** Olix has already proven its competitive edge in liver targeting through its proprietary GalNAc conjugation technology. The firm is aggressively advancing its next-generation capabilities, directly targeting adipose tissue and BBB-penetrating siRNA platforms. In response to global industry trends— Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and other global leaders are introducing novel delivery systems to enter the CNS space—Olix is refining its own proprietary BBB shuttle and next-generation siRNA technologies. As 2026 brings clearer readouts from preclinical obesity data and clinical results for MASH therapy, Olix is likely to rerate.

AT A GLANCE

Current price	**KRW196,300**
Market cap	KRW3,963b
Shares (float)	20,190,000 shares
120-day avg. trading volume	KRW108b
52-week low/high	KRW34,800 / KRW196,300
Relative return (3m/6m)	36.0% / 60.8%
Dividend yield (2025P)	n/a
BVPS (2025P)	n/a
Floating share ratio	82.9%
Foreign ownership	10.4%
Major shareholder	Dong-ki Lee et al. (17.1%)

Key data

	2022	2023	2024	2025P
Revenue (KRWb)	9	17	6	15
Operating profit (KRWb)	(22)	(18)	(31)	(30)
Net income (controlling) (KRWb)	(22)	(19)	(41)	(16)
EPS (adj) (KRW)	(1,260)	(1,139)	(2,369)	n/a
EPS (adj) growth (%)	nm	nm	nm	n/a
EBITDA margin (%)	(217.8)	(91.1)	(498.4)	n/a
ROE (%)	(46.2)	(33.0)	(120.1)	n/a
P/E (adj) (x)	n/a	n/a	n/a	n/a
P/B (x)	5.2	4.9	19.9	n/a
EV/EBITDA (x)	(13.6)	(16.5)	(14.1)	n/a
Dividend yield (%)	0.0	0.0	0.0	n/a

Note: Based on Mar 5 close
Source: Olix Pharmaceuticals, Samsung Securities

Circumventing competitor's patents

Olix has built a patent-protected platform advantage

- Olix has developed a proprietary siRNA platform designed to navigate around Alnylam's patent portfolio, anchored by its: 1) asymmetric siRNA structure; and 2) GalNAc conjugation technology. A key differentiator is Olix's guide strand: a 21-nt RNA sequence without the conventional 3' dTdT overhang. This design improves RISC complex formation and hAgo2 binding affinity, delivering more than a 6x increase in potency.
- The company has strengthened its position by identifying novel targets through genome-wide association study (GWAS) and validating their therapeutic potential in clinical studies.

Olix Pharmaceuticals: Main platform technology



Source: Olix Pharmaceuticals, Samsung Securities

Olix Pharmaceuticals: Pipeline

Category	Drug	Indication	Status	Partner
Liver	OLX702A	MASH/Obesity	P1 (Australia)	Eli Lilly
	OLX706A	Cardiovascular	Preclinical	Hansoh Pharma
	OLX706B	Metabolic disease	Animal POC	Hansoh Pharma
	OLX706C	Cardiovascular	Preclinical	Hansoh Pharma
	OLX702X	Obesity	Discovery	
	OLX702R	Hypertension	Discovery	
Skin	OLX104C	Hair loss	P1b/2a (Australia)	
	OLX101A	Hypertrophic scar	P2a completed (US)	
Eye	OLX301A	Dry/wet AMD	P1 completed (US)	
	OLX304C	Retinitis pigmentosa	Animal POC	
Adipocyte	OLX501A	Obesity	Animal POC	
Dual Targeting Platform		Metabolic, CVD, Obesity, etc.	Animal POC	
CNS Targeting Platform		Brain disease	Platform development	

Note: R&D underway via partnership with L'Oreal in skin/hair regeneration (details undisclosed)
Source: Samsung Securities

Why did Lilly pick Olix?

▶ Why Lilly chose Olix

- OLX702A (MARC1 RNAi): OLX702A, licensed to Eli Lilly, is currently undergoing Phase 1 MAD in Australia, and dosings are expected to be completed in 2Q26. There is also the potential for option rights to be exercised on dual-target programs, including MARC1 RNAi. MARC1 variants are associated with NAFLD progression & liver-related mortality. This candidate does not overlap with any of Lilly's internal siRNA programs, giving it unique, non-redundant value.
- A single dose of OLX702A demonstrated sustained efficacy for over 10 months, significantly longer than the typical 6-month half-life of standard GalNAc-siRNA conjugates. As a standalone therapy, it has demonstrated superior efficacy, reducing liver fat by 60-80%. To date, no safety concerns or adverse events have been reported.

Olix Pharmaceuticals: Joint development and license contract details

Date	Contract subject	Size	Indication	Partner	Status
Oct 2021	GalNAc-asiRNA Platform	USD451m	Cardiovascular & metabolic candidates	Hansoh Pharma	Main Contract: Olix provides two new drug candidates for targets presented by Hansoh Pharma using its GalNAc-asiRNA platform technology. Option Contract: Hansoh Pharma can exercise an option for up to two additional candidates using Olix's GalNAc-asiRNA-based technology until 90 days after Olix completes the derivation of the first candidate under the main contract.
Feb 2025	OLX702A	USD630m	MASH/Obesity	Eli Lilly	Exclusive License: Upon signing the contract, Olix grants an exclusive license to Lilly. Olix is responsible for continuing and completing Phase I clinical activities for OLX702A, while Lilly will handle subsequent research, development, and commercialization. ※ If a therapeutic is developed to target the MARC1 gene and one or more other target genes simultaneously, Lilly holds priority rights to that therapeutic. This may result in an increase in the total contract value or lead to exclusive negotiations.
Jun 2025	Undisclosed	Millions of euros (details undisclosed)	Skin/hair regeneration & longevity	L'Oréal	Olix performs the development of skin and hair-related collaboration products using siRNA technology. At Olix's request, L'Oréal provides advisory and non-binding guidance regarding these results. ※ L'Oréal holds the exclusive negotiation rights to enter additional joint research contracts (Additional Joint Research Rights), which include, but are not limited to, licensing out agreements.

Source: Olix Pharmaceuticals, Samsung Securities

Possibility of more out-licensing deals

- **Preparations are underway to position ALK7 siRNA as a compelling licensing opportunity. Need to check whether siRNA delivery occurs in adipose tissue through systemic delivery**
  - Mechanism: The liver secretes INHBE (Activin E), which binds to ALK7 receptors on adipocytes, inhibiting fat breakdown and promoting lipid storage. ALK7 siRNA selectively disrupts this pathway, enhancing lipolysis and reducing visceral and hepatic fat—without the muscle-wasting effects associated with GLP-1 agonists.
  - Competitive landscape: Clinical data on Arrowhead Pharmaceuticals' ARO-INHBE program were released simultaneously. This candidate leverages the inherent strengths of siRNA technology—durable target suppression and adipose-specific delivery—to offer a distinct alternative to GLP-1-based therapies with minimal muscle loss (which is commonly seen with GLP-1 agonists).
  - Olix is estimated to be 2-3 years behind other developers of ALK7-targeted programs. The company should open the door to out-licensing discussions once it presents compelling, differentiated data.

INHBE/ALK7 mechanism of action



Source: Arrowhead, Samsung Securities

Comparison of INHBE/ALK7 siRNA pipelines, by company

Company	Pipeline	Target	Stage	Note
Arrowhead	ARO-INHBE	INHBE	P1/2	TRiM delivery: Visceral fat -23.2% with Mounjaro; -15.6% mono.
	ARO-ALK7	ALK7	P1/2	TRiM delivery: Visceral fat -14.1% with one 8-week dose.
Alnylam	ALN-INHBE	INHIBE	Preclinical	GalNAc delivery used
	ALN-2232	ALK7	Preclinical	C16 delivery used
Wave Life Sciences	WVE-007	INHBE	P1	GalNAc delivery: Body fat -4.5% in 3 months.
Olix Pharma	OLX501A	ALK7	Preclinical	Delivery undisclosed: Monkey data to be announced.

Source: Samsung Securities

Rznomics (476830; Not rated)

- **Multi-correction platform based on trans-splicing ribozyme:** Rznomics has developed a proprietary bidirectional RNA editing platform powered by trans-splicing ribozyme technology, which simultaneously cleaves target mRNAs and ligates corrective sequences to restore normal protein function. Unlike ADAR enzyme-based single-nucleotide substitution approaches (*eg*, Wave Life Sciences), Rznomics' platform operates via a unique, endogenous cellular mechanism, enabling independent technological differentiation. Moving beyond the limitations of conventional therapies—capable of correcting only a single mutation—Rznomics has demonstrated multi-correction capability: A single therapeutic agent can correct multiple variants simultaneously. This compelling advantage was a key factor in Eli Lilly's selection of Rznomics as a strategic partner.
- **Pipeline update:** RZ-001 (hepatocellular carcinoma & glioblastoma) is a dual-mechanism anticancer agent that corrects hTERT mutations while expressing HSV-tk to enable prodrug activation. It is currently in Phase Ib/IIa clinical trials. Interim data from a cohort of patients with primary hepatocellular carcinoma receiving the combination of Atezolizumab (Tecentriq) + Bevacizumab (Avastin) + RZ-001 are expected to be presented orally at the 2026 AACR meeting. In the Phase III IMbrave150 trial (Atezolizumab + Bevacizumab as first-line HCC), the objective response rate (ORR) was 27.3-30% with complete response (CR) rates of 8-11%. If RZ-001 add-on therapy can elevate ORR to more than 40%, it would establish a compelling competitive advantage. Updates on the glioblastoma trial are anticipated in 2H26.
- **Collaboration with Eli Lilly underway:** In May 2025, Rznomics entered a USD1.3b option agreement with Eli Lilly to co-develop a therapeutic for hereditary hearing loss. The program is currently in the discovery phase, with candidate selection expected to trigger the first milestone payment. Eli Lilly retains the right to extend the collaboration to multiple therapeutic targets. Lilly recognizes hereditary hearing loss as a genetically heterogeneous disease that cannot be addressed by a single modality. To build a comprehensive portfolio, Lilly has pursued a multi-pronged strategy: 1) development of the pipeline it secured through acquiring Akouos (and its AAV-based gene therapy AK-OTOF for OTOF-related deafness); and 2) partnering with Seamless Therapeutics (a DNA editing platform company). Rznomics' trans-splicing ribozyme platform is viewed not as a competitor, but as a complementary technology within Lilly's broader genetic medicine ecosystem. Additional pipeline candidates—RZ-003 (Alzheimer's disease) and RZ-004 (Retinitis Pigmentosa)—are currently undergoing platform validation under material transfer agreements (MTAs).
- **Investment considerations:** The strategic partnerships with global pharmas provide strong validation of Rznomics' platform versatility. However, the company faces multiple long-term hurdles, such as: 1) the pipeline remaining in early clinical stages, with limited efficacy data publicly available; 2) the undisclosed scale of potential technology licensing deals; 3) size constraints of AAV vectors limiting payload capacity; and 4) immune responses to the systemic delivery of AAV vectors.

AT A GLANCE

Current price	**KRW151,100**
Market cap	KRW2,105b
Shares (float)	13,934,000 shares
120-day avg. trading volume	KRW120b
52-week low/high	KRW90,000 / KRW193,900
Relative return (3m/6m)	n/a
Dividend yield (2025P)	n/a
BVPS (2025P)	n/a
Floating share ratio	77.5%
Foreign ownership	1.8%
Major shareholder	Sung-wook Lee et al. (16.6%)

Key data

	2022	2023	2024	2025P
Revenue (KRWb)	0	0	0	7
Operating profit (KRWb)	(19)	(16)	(13)	(15)
Net income (controlling) (KRWb)	(32)	(14)	(19)	(105)
EPS (adj) (KRW)	(3,927)	(1,602)	(2,146)	n/a
EPS (adj) growth (%)	nm	nm	nm	n/a
EBITDA margin (%)	n/a	(10,143.2)	n/a	n/a
ROE (%)	61.9	19.8	22.4	n/a
P/E (adj) (x)	n/a	n/a	n/a	n/a
P/B (x)	n/a	n/a	n/a	n/a
EV/EBITDA (x)	n/a	n/a	n/a	n/a
Dividend yield (%)	n/a	n/a	n/a	n/a

Note: Based on Mar 5 close
Source: Rznomics, Samsung Securities

Evolution of RNA editing platform and global big-pharma partnerships

▶ Validation of broad applicability and commercial potential of its platform technology through Eli Lilly collaboration

- Trans-splicing ribozyme technology: Rznomics' proprietary bidirectional RNA editing platform uniquely enables precise cleavage of disease-causing target mRNAs while simultaneously ligating a corrected genetic sequence to restore normal protein function.
- Collaboration with Eli Lilly: Rznomics has entered into a USD1.3b option agreement with Eli Lilly to co-develop a therapeutic for hearing loss. Eli Lilly is providing research funding to advance Rznomics' lead candidate.

Rznomics: Main platform technology



Source: Samsung Securities

Rznomics: Joint development and license contract details

Category	Details
Partner	• Eli Lilly, US
Contract type	• Research Collaboration and License Agreement
Technology	• RNA substitution enzyme platform (trans-splicing ribozyme) (candidate discovery by target, target-specific RNA substitutio n enzyme, and vector optimization technology)
Details	• Transfer of joint research and commercialization rights for hereditary hearing loss treatments using Rznomics' RNA substitution enzyme platform technology (milestone payments to be received according to pre-determined conditions upon exercising development options per target) • Rznomics is responsible for early-stage research and candidate discovery, while Eli Lilly is responsible for late-stage development such as preclinical/clinical trials, production, and commercialization • Separate payment of research fees per target within limits and royalties based on annual target sales volume
Period	• May 13, 2025 ~ Until the end of the royalty period
Total value	• USD1.3b, running royalties separate

Source: Rznomics, Samsung Securities

Platform validation through clinical proof-of-concept (PoC) of RZ-001

Enhancing technical safety & credibility of subsequent pipelines through the acquisition of the first human clinical data

- The successful demonstration of clinical PoC for RZ-001—Rznomics' first-in-human clinical data; set to be announced in 2026—should serve as the first critical milestone proving that its proprietary RNA editing platform functions effectively in humans.
- This validation should significantly enhance confidence in the technical safety of the platform and bolster the perceived likelihood of success for downstream pipeline candidates, including RZ-003 and RZ-004 (using the same platform).
- The first clinical proof of the platform's efficacy should: 1) substantially strengthen Rznomics' negotiating position in future technology licensing discussions with global pharma giants; and 2) trigger a comprehensive revaluation of the company's entire pipeline.

Rznomics: Pipeline

Category	Pipeline/MoA	Indication	Nation (trial)	Milestone	Phase	Partner
Oncology	RZ-001 (hTERT RNA cleavage, fused with HSV-tk to selectively kill cancer cells)	Liver cancer (immune combination)	Korea/US	FDA Fast track (Feb 2025) FDA ODD (Jan 2024)	P1b/2a (combo)	Trial partnership (free drug supply) Roche, Celltrion
		Glioblastoma	Korea/US	FDA Fast track (Nov 2023) FDA ODD (Oct 2024)	P1/2a Part A	
Degenerative	RZ-003 (Mutant ApoE4 RNA cleavage and replacement with WT ApoE4)	Alzheimer's disease	Korea/US		Pre-clinical	MTA with global company
Ophthalmic	RZ-004 (Mutant RHO RNA cleavage and replacement with WT RHO)	Retinitis pigmentosa	Australia		P1b/2a Part A	MTA with global company
Neurodevelopmental disorders	RZ-005 (Mutant MeCP2 RNA cleavage and replacement with WT MeCP2)	Rett syndrome	Korea/US		Candidate deriving	
Other	Platform License Deal					May 2025, Research collaboration and license agreement Eli Lilly

Source: Rznomics, Samsung Securities

Compliance Notice

- During the one year prior to 3/26 2026, Samsung Securities had participated as an underwriter in an IPO for Rznomics Inc..
- As of 3/26 2026, the covering analyst(s) did not own any shares, or debt instruments convertible into shares, of any company covered in this report.
- As of 3/26 2026, Samsung Securities' holdings of shares and debt instruments convertible into shares of each company covered in this report would not, if such debt instruments were converted, exceed 1% of each company's outstanding shares.
- This report has been prepared without any undue external influence or interference, and accurately reflects the views of the analyst(s) covering the company or companies herein.
- All material presented in this report, unless specifically indicated otherwise, is under copyright to Samsung Securities.
- Neither the material nor its content (including copies) may be altered in any form, or by any means transmitted, copied, or distributed to another party, without prior express written permission from Samsung Securities.
- This memorandum is based upon information available to the public. While we have taken all reasonable care to ensure its reliability, we do not guarantee its accuracy or completeness. This memorandum is not intended to be an offer, or a solicitation of any offer, to buy or sell the securities mentioned herein. Samsung Securities shall not be liable whatsoever for any loss, direct or consequential, arising from the use of this memorandum or its contents. Statements made regarding affiliates of Samsung Securities are also based upon publicly available information and do not necessarily represent the views of management at such affiliates.
- This material has not been distributed to institutional investors or other third parties prior to its publication.

Target price/Rating changes in past two years (as of Mar 5)







Target price/Rating changes in past two years (as of Mar 5)

ST Pharm									
Date	2023/11/2	2024/4/18	6/13	9/9	2025/4/21	10/30	12/1	2026/1/26	2/10
Recommendation	BUY	BUY	BUY	BUY	BUY	BUY	BUY	BUY	BUY
Target price (KRW)	90,000	100,000	120,000	130,000	110,000	130,000	150,000	170,000	190,000
Gap* (average)	-22.92	-6.16	-21.35	-32.21	-21.42	-22.04	-16.82	-9.79	
(max or min)**	7.00	9.60	-3.83	-10.00	-3.91	-10.00	-6.93	-5.53	
Olix Pharmaceuticals									
Date	2026/3/5								
Recommendation	Not Rated								
Target price (KRW)	n/a								
Gap* (average)									
(max or min)**									
Rznomics									
Date	2026/3/5								
Recommendation	Not Rated								
Target price (KRW)	n/a								
Gap* (average)									
(max or min)**									

Target price/Rating changes in past two years (as of Mar 5)

Samsung Securities uses the following investment ratings*

Company

BUY	Expected to increase in value by 15% or more within 12 months and is highly attractive within sector
HOLD	Expected to increase/decrease in value by less than 15% within 12 months
SELL	Expected to decrease in value by 15% or more within 12 months

Industry

OVERWEIGHT	Expected to outperform market by 5% or more within 12 months
NEUTRAL	Expected to outperform/underperform market by less than 5% within 12 months
UNDERWEIGHT	Expected to underperform market by 5% or more within 12 months

* Note: Effective Jul 27, 2023, BUY, HOLD, and SELL criteria are based on expectations of share-price moves of 15% or more within 12 months

Percentage of ratings in 12 months prior to 2025.12.31

BUY(85.8%)·HOLD(14.2%)·SELL(0%)

Samsung Securities

SAMSUNG SECURITIES
Samsung Electronics Bldg., 11, 74-gil,
Seochodae-ro, Seocho-gu, Seoul, Korea 06620
Tel: 02 2020 8000 / www.samsungpop.com

Family Center: 1588 2323

Voice Of Customer: 080 911 0900

Member of
Dow Jones
Sustainability Indices
Powered by the S&P Global CSA